Patients taking dasatinib should be monitored for which of the following potential adverse effects?

Patients taking dasatinib, a tyrosine kinase inhibitor primarily used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), should be monitored for fluid retention as a significant potential adverse effect. Dasatinib can induce fluid retention through its effects on signaling pathways related to sodium and fluid regulation in the body. This can manifest as peripheral edema, pleural effusion, or pulmonary edema, making it essential for healthcare providers to monitor patients for signs of these complications.

In managing dasatinib therapy, it is critical to recognize symptoms of fluid overload early and address them promptly. Monitoring can involve regular assessments of weight, observing for swelling in limbs, and evaluating for respiratory symptoms that may indicate pleural effusion. This vigilance helps mitigate the risks associated with fluid retention, enhancing patient safety and treatment efficacy.